Interleukin 10 Gene Transfer Prevents Experimental Colitis in Rats

Overview

Journal Gut

Specialty Gastroenterology

Date 2000 Feb 15

PMID 10673295

Citations 47

Authors

G Barbara

Z Xing

C M Hogaboam

J Gauldie

S M Collins

Affiliations

Soon will be listed here.

Abstract

Background: The development of colitis in interleukin 10 (IL-10) deficient mice, together with the known anti-inflammatory and immunomodulatory properties of this cytokine have prompted consideration of IL-10 as a treatment for inflammatory bowel disease (IBD). However, studies using hrIL-10 in IBD models have yielded inconsistent results.

Aims: To examine the therapeutic potential of overexpressing the IL-10 gene before and after the induction of experimental colitis in rats.

Methods: Gene transfer was achieved by intraperitoneal injection of non-replicating human type 5 adenovirus bearing the IL-10 gene, either 24 hours before or one hour after intrarectal administration of dinitrobenzene sulphonic acid in rats. Colonic damage and inflammation was assessed macroscopically and by measuring myeloperoxidase activity and leukotriene B4 concentrations.

Results: Gene transfer increased IL-10 protein in serum for up to six days. IL-10 gene transfer prior to colitis improved colitis macroscopically and histologically, and significantly reduced colonic myeloperoxidase activity and leukotriene B4 concentrations. In contrast, IL-10 gene transfer after the onset of colitis had no beneficial effect.

Conclusions: Gene therapy using an adenovirus-IL-10 construct was successful in preventing but not in reversing experimental colitis in the rat.

Citing Articles

α-Terpineol Mitigates Dextran Sulfate Sodium-Induced Colitis in Rats by Attenuating Inflammation and Apoptosis.

Khan R, Jori C, Ansari M, Ahmad A, Nadeem A, Siddiqui N ACS Omega. 2023; 8(32):29794-29802.

PMID: 37599911 PMC: 10433518. DOI: 10.1021/acsomega.3c04317.

Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord.

Izco M, Schleef M, Schmeer M, Carlos E, Verona G, Alvarez-Erviti L Pharmaceutics. 2023; 15(4).

PMID: 37111717 PMC: 10145068. DOI: 10.3390/pharmaceutics15041230.

A Chemically Induced Experimental Colitis Model with a Simple Combination of Acetic Acid and Trinitrobenzene Sulphonic Acid.

Cinpolat H, Bugdayci G, Sengul N, Astarci H Turk J Gastroenterol. 2022; 34(3):196-202.

PMID: 36511608 PMC: 10152155. DOI: 10.5152/tjg.2022.22174.

Macrophage orchestration of epithelial and stromal cell homeostasis in the intestine.

Cao Q, Tyler Mertens R, Sivanathan K, Cai X, Xiao P J Leukoc Biol. 2022; 112(2):313-331.

PMID: 35593111 PMC: 9543232. DOI: 10.1002/JLB.3RU0322-176R.

Long noncoding RNA Gm31629 protects against mucosal damage in experimental colitis via YB-1/E2F pathway.

Feng X, Xiao Y, He J, Yang M, Guo Q, Su T JCI Insight. 2022; 7(6).

PMID: 35143419 PMC: 8986069. DOI: 10.1172/jci.insight.150091.

References

De Vries J . Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med. 1995; 27(5):537-41. DOI: 10.3109/07853899509002465. View

Krakauer T . IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial cells. Immunol Lett. 1995; 45(1-2):61-5. DOI: 10.1016/0165-2478(94)00226-h. View

Drazan K, Wu L, Bullington D, Shaked A . Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg. 1996; 31(3):411-4. DOI: 10.1016/s0022-3468(96)90749-6. View

Berg D, Davidson N, Kuhn R, Muller W, Menon S, Holland G . Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996; 98(4):1010-20. PMC: 507517. DOI: 10.1172/JCI118861. View

Herfarth H, Mohanty S, Rath H, Tonkonogy S, Sartor R . Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut. 1996; 39(6):836-45. PMC: 1383456. DOI: 10.1136/gut.39.6.836. View

Piedimonte G, Pickles R, Lehmann J, McCarty D, Costa D, Boucher R . Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation. Am J Respir Cell Mol Biol. 1997; 16(3):250-8. DOI: 10.1165/ajrcmb.16.3.9070609. View

Xing Z, Ohkawara Y, Jordana M, Graham F, Gauldie J . Adenoviral vector-mediated interleukin-10 expression in vivo: intramuscular gene transfer inhibits cytokine responses in endotoxemia. Gene Ther. 1997; 4(2):140-9. DOI: 10.1038/sj.gt.3300371. View

Sferra T, McNeely D, Johnson P . Gene transfer to the intestinal tract: a new approach using selective injection of the superior mesenteric artery. Hum Gene Ther. 1997; 8(6):681-7. DOI: 10.1089/hum.1997.8.6-681. View

Ribbons K, Thompson J, Liu X, Pennline K, Clark D, Miller M . Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Eur J Pharmacol. 1997; 323(2-3):245-54. DOI: 10.1016/s0014-2999(97)00017-4. View

10.

Brown G, Thiele D, Silva M, Beutler B . Adenoviral vectors given intravenously to immunocompromised mice yield stable transduction of the colonic epithelium. Gastroenterology. 1997; 112(5):1586-94. DOI: 10.1016/s0016-5085(97)70040-4. View

11.

van Deventer S, Elson C, Fedorak R . Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997; 113(2):383-9. DOI: 10.1053/gast.1997.v113.pm9247454. View

12.

Keel M, Ungethum U, Steckholzer U, Niederer E, Hartung T, Trentz O . Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood. 1997; 90(9):3356-63. View

13.

Hogaboam C, Vallance B, Kumar A, Addison C, Graham F, Gauldie J . Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest. 1998; 100(11):2766-76. PMC: 508481. DOI: 10.1172/JCI119823. View

14.

Hamilton T, McClane S, Baldwin S, Burke C, Patel H, Rombeau J . Efficient adenoviral-mediated murine neonatal small intestinal gene transfer is dependent on alpha(v) integrin expression. J Pediatr Surg. 1998; 32(12):1695-703. DOI: 10.1016/s0022-3468(97)90508-x. View

15.

Wallace J, McKnight W, Asfaha S, Liu D . Reduction of acute and reactivated colitis in rats by an inhibitor of neutrophil activation. Am J Physiol. 1998; 274(5):G802-8. DOI: 10.1152/ajpgi.1998.274.5.G802. View

16.

MacDonald T . Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel disease. Gut. 1998; 42(4):460-1. PMC: 1727060. DOI: 10.1136/gut.42.4.460. View

17.

During M, Xu R, Young D, Kaplitt M, Sherwin R, Leone P . Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med. 1998; 4(10):1131-5. DOI: 10.1038/2625. View

18.

Marshall J, Leal-Berumen I, Nielsen L, Glibetic M, Jordana M . Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest. 1996; 97(4):1122-8. PMC: 507161. DOI: 10.1172/JCI118506. View

19.

DE Wet J, Wood K, DeLuca M, Helinski D, Subramani S . Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol. 1987; 7(2):725-37. PMC: 365129. DOI: 10.1128/mcb.7.2.725-737.1987. View

20.

Boughton-Smith N, Wallace J, Whittle B . Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions. 1988; 25(1-2):115-23. DOI: 10.1007/BF01969102. View